Gapping up
In reaction to earnings/guidance:
- MSTR +15%, SWKS +12.6% (also approves a new $2 bln stock repurchase program), ERIC +12.3%, WDC +9.8%, RHI +8.8%, ABCB +8.7%, X +6.7%, FHI +5.8%, HLI +4.4%, MATW +4.2%, HTH +3.2%, LYB +3%, DLB +2.9%, LLY +2.9%, ETH +2.8%, FFBC +2.4%, NATI +2.3%, PKX +2.1%, SF +1.9%, SYF +1.7%, FICO +1.6%, AJG +1.4%, JCI +1.3%, PSXP +1.3%, WY +1.2%, CE +1.1% (also increases dividend), TEAM +0.9%, CAT +0.8%
Other news:
- GME +76.7% (extends momentum)
- AMC +43.2% (extends momentum)
- BLCM +38% (FDA lifts clinical hold on Phase 1/2 trial evaluating BPX-601)
- NVAX +37.4% (says its COVID vaccine candidate shows efficacy of 89.3% in Phase 3 trial in the UK)
- ALUS +21.8% (FREYR to List on NYSE through a business combination with Alussa Energy Acquisition Corp)
- BIIB +11.8% (Biogen and Eisai (ESALY) announce FDA's 3-month extension of review period for the Biologics License Application for aducanumab; PDUFA action date is June 7, 2021)
- CBMG +8.9% (received written notice from CFIUS that it had concluded its review of the CBMG Holdings merger and there were no unresolved national security concerns associated; continues to target completion in February 2021)
- PACE +6.4% (Nerdy to become public company via business combination with TPG Pace Tech Opportunities)
- FUBO +5% (prices $350 mln of 3.25% convertible senior notes due 2026)
- BTAI +4.3% (FDA grants orphan drug designation for BXCL701)
- TTI +4.2% (divests interests in CSI Compressco LP And Related Assets for $30.7 mln, provides Q4 guidance)
- ACIU +3.3% (reports progress for therapeutic programs targeting the NLRP3 inflammasome pathway)
- OSUR +3% (OraSure subsidiary DNA Genotek's OMNIgene ORAL included in EUA granted to ambry genetics for use in COVID-19 RT-PCR saliva test)
- NBTX +2.3% (first patient has been injected in a phase I study evaluating NBTXR3)
- RDHL +2% (announces positive DSMB futility review for Phase 2/3 COVID-19 study of opaganib)
- ABG +1.4% (increases its share repurchase authorization)
Analyst comments:
- SLM +6.5% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- ICHR +2.9% (upgraded to Outperform from Market Perform at Cowen)
- UCTT +2% (upgraded to Outperform from Market Perform at Cowen)
- BA +1.4% (upgraded to Overweight from Underweight at Morgan Stanley)